Skip to content
June 29, 2022

Equity.Guru

Investment information for the new generation

orphan drug designation

Medexus Pharmaceuticals (MDP.T) today announced its financial results and provided a business update for the three-month period ended June 30, 2021.   “We continued to see pressure on IXINITY® ex-factory…
PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also…
Pharmadrug’s (BUZZ.C) subsidiary Sairiyo Therapeutics received their orphan drug designation (ODD) for dimethyltryptamine (DMT) from the United States Food and Drug Administration (FDA) for the prevention of ischemia-reperfusion injury…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a press release. PharmaTher is…